Drugs / BI 1703880
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05471856 | Feb 2023 → Sep 2028 expected | cancer | Boehringer Ingelheim | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 1703880 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05471856 ↗ |
| Action | Activate | “BI 1703880 is a new drug that has been developed to activate the immune system” PMID 39817655 ↗ Jan 2025 |
| Route | Intravenous | “Participants get BI 1703880 and ezabenlimab as infusions into a vein.” NCT05471856 ↗ |